Published in Cancer Weekly, September 3rd, 2002
Current antilymphoma and leukemic therapies destroy normal bone marrow cells and suppress the immune system. However, this preclinical study demonstrates that CT-32228 inhibition of LPAAT selectively destroyed only the cancerous cells leaving the immune system cells unaffected.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.